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To the editor, 
We have previously reported that mice lacking three components of the epidermal cornified 
envelope – Envoplakin, Periplakin and Involucrin – (EPI-/- mice) exhibit several hallmarks of 
atopic dermatitis and are resistant to developing chemically induced skin tumours [1, 2].  EPI-
/- mice have an enhanced skin bacterial load and exhibit upregulation of a variety of anti-
microbial proteins (AMPs), including -defensins and S100A9 [3].  
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When analysing a previously published dataset of genes that are differently expressed in the 
skin of EPI-/- and wild type (WT) mice, we noticed a more than 3-fold increase in expression 
of Galectin-6 [2]. Galectins are a family of lectins with binding specificity for - galactosides 
[4]. Although the function of Galectin-6 has not been characterized, several galectin family 
members have antimicrobial activity, targeting blood group positive microbes [5]. This led us 
to hypothesise that Galectin-6 is a novel skin AMP.  
 
When EPI-/- mice are housed under conventional conditions, the skin microbiota, as 
quantitated by 16S ribosomal RNA levels, is approximately three-fold more abundant than in 
WT controls [3] (see Supplementary Information for details of mice and experimental 
techniques). However, when EPI-/- mice are housed under specific pathogen-free (SPF) 
conditions the bacterial load falls to that of WT mice [3]. We confirmed that Galectin-6 mRNA 
was significantly higher in EPI -/- mice (Figure 1A). Furthermore, in contrast to the AMPs 
analysed previously [3], Galectin-6 expression was decreased in the skin of EPI -/- mice 
housed under SPF conditions (Figure 1A).  
 
By comparing levels of Galectin-6 in total skin, from which the adipocyte layer had been 
removed, and epidermis, we could show that Galectin-6 is more abundant in the dermis than 
the epidermis (Figure 1A). This is of interest, given that bacteria can penetrate the living 
epidermal layers in EPI -/- mice [3]. Since galectin-6 gene expression in WT skin was not 
altered when WT mice were housed under SPF conditions (Supplementary Figure 1), 
galetin-6 is likely to respond to an abundant skin flora when the epidermal barrier is 
defective, but not to microbial load under steady state conditions. 
 
Amongst galectin family members, galectin-4 shares more than 80% sequence homology 
with galectin-6. Lgals6 represents a duplication of the galectin-4 gene, and the two genes 
share 8 out of 10 exons [6]. However, expression of other galectins, including galectin-4, did 
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not differ between EPI-/- and WT whole skin, irrespective of whether or not the EPI-/- mice 
were maintained under SPF conditions (Figure 1B).  
 
Given its unusual expression in EPI-/- skin, we investigated whether Galectin-6 has anti-
microbial activity. A range of bacterial strains were grown in the presence of recombinant 
Galectin-6 or control protein expressing GST tag only. As previously reported for Galectin-4 
and Galectin-8 [7], Galectin-6 suppressed the growth of E. coli expressing blood group 
antigen (E.coli O86, possessing blood group-B antigen), in a dose-dependent manner 
(Figure 1C), and did not affect the growth of non-blood group antigen-expressing E.coli or 
other bacterial strains tested (Figure 1D). The antimicrobial activity of galectin-6 was similar 
to that of murine galectin-4 (Supplementary Figure 2). We conclude that Galectin-6 is a 
novel AMP, the expression of which can be modulated by skin bacterial load. 
 
Galectin-6 differs from the other AMPs we have examined in being regulated by bacterial 
load in EPI-/- skin. This is all the more remarkable, given that its abundance is low in the 
epidermis relative to total skin. Lgals6 is also unusual in that it does not have a human 
homologue and is present in some mouse species, including 129sv, but not in others, such 
as C57BL/6 and Balb/c [6]. Even though Galectin-4 and Galectin-6 are highly conserved, 
their expression patterns in the digestive tract differ following challenge with dextran sodium 
sulfate [8]. This is consistent with the differential regulation of Lgals6 and Lgals4 by the skin 
microbiota. Furthermore, previously published microarray data show that Lgals4 expression 
is not significantly altered in atopic dermatitis and psoriatic skin compared with normal 
controls (GSE26952) [9]. We cannot exclude the possibility that skin barrier defects also 
contributed to the upregulated expression of Lgals6 in EPI-/- mice, because the level in flora-
deficient EPI-/-mice was still higher than that of controls. Nevertheless, our findings reveal 
that Galectin-6, unlike other AMPs [3] is influenced by the abundance of skin microbiota. We 
also do not rule out additional functions for Galectin-6 in the skin; for example in the dermis it 
could potentially modulate fibrosis, as in the case of galectin-3 in the lung [10].  
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Figure 1. Lgals6 expression and function in skin (A) qRT-PCR of Lgals6 in WT, EPI-/- 
and flora-deficient EPI-/- skin and epidermis. (B) qRT-PCR of genes encoding other galectins 
(Lgals1, Lgals3, Lgals4, Lgals7, Lgals8, Lgals9 and Lgals12) in WT, EPI-/- and flora-deficient 
EPI-/- whole skin. Data are means ± SEM from at least 4 mice per group. (C) Antimicrobial 
properties of recombinant galectin-6 (closed circles) or tag protein (open squares) on blood 
group antigen-expressing E.coli (O86) growth. (D) Growth of non-blood group antigen-
expressing E.coli (O6), P. aeruginosa, S. epidermidis and S. aureus treated with the 
recombinant galectin-6 or tag protein. See supplemental information for methodology and 
reagents. P-values are indicated with: * p<0.05, *** p <0.001. 
 
